BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening

Glioblastoma multiforme (GBM), the most common type of primary brain tumor, is universally fatal, with a median survival duration ranging from 12-15 months despite maximum treatment efforts. Temozolomide (TMZ) is the current standard of care for GBM patients; however patients usually develop resista...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Cancer Res
Autori principali: Ding, Jie, Wu, Shaofang, Zhang, Chen, Garyali, Arnav, Martinez-Ledesma, Emmanuel, Gao, Feng, Pokkulandra, Adarsha, Li, Xiaolong, Bristow, Christopher, Carugo, Alessandro, Koul, Dimpy, Yung, WK Alfred
Natura: Artigo
Lingua:Inglês
Pubblicazione: e-Century Publishing Corporation 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895442/
https://ncbi.nlm.nih.gov/pubmed/31815044
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi